We hypothesized that HIV-1 can evade NK cell recognition through the selection of sequence polymorphisms within regions targeted by KIRs, and that KIR-associated polymorphisms within the HIV-1 sequence can be identified on a population level. To test this hypothesis, we examined the relationship between KIR genotypes and HIV-1 polymorphisms in a cohort of 91 untreated chronically HIV-1-infected individuals ([Supplemental Table 1](#SD2){ref-type="supplementary-material"}) in whom full-length HIV-1 sequences were determined, and HLA class I associated polymorphisms were previously described^[@R9]^. We used a decision-tree approach which corrects for phylogenetic structure among the sequences and allows for a multivariate analysis to identify KIR-associated sequence polymorphisms^[@R10]^. This analysis led to the identification of 22 positions within the HIV-1 genome in which amino acid polymorphisms were significantly associated with the presence of a specific KIR gene ([Table 1](#T1){ref-type="table"} and [supplemental figure 1](#SD1){ref-type="supplementary-material"}). Taken together, these data show that HIV-1 can adapt to host KIR genotypes on a population level.

To assess the consequences of these KIR-associated amino acid sequence polymorphisms within HIV-1 on NK cell mediated recognition of HIV-1 infected cells, we initially evaluated observed polymorphisms that occurred within a region of HIV-1 encoding for an overlapping segment that spans the C-terminal end of Vpu and the N-terminal end of Env (Polymorphisms \#15--18 in [Table 1](#T1){ref-type="table"} and [Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). We selected this region as these polymorphisms were present within both reading frames at significantly higher frequencies in individuals that possessed at least one copy of the KIR2DL2 gene compared to individuals that did not ([Table 2](#T2){ref-type="table"}, and [Supplemental Tables 2--3](#SD2){ref-type="supplementary-material"}). In amino acid positions 71 and 74 of Vpu, HIV-1 sequences derived from KIR2DL2+ individuals encoded for a methionine (M) in position Vpu71 and a histidine (H) in position Vpu74 in over 70% of cases. Because of the overlapping Vpu/Env coding region, these positions of Vpu corresponded to a tryptophan (W) in position Env17 and a methionine (M) in position Env20, respectively. The Vpu71M/74H (Env17W/20M) sequence was significantly less frequent in HIV-1-infected individuals that did not encode for KIR2DL2 (p \< 0.0001). Furthermore, the presence of the Vpu71M polymorphism was in strong linkage disequilibrium with the Vpu74H polymorphism (p = 3.17^−12^). Taken together, these data demonstrate a significant enrichment for HIV-1 viruses containing the Vpu71M/74H (Env17W/20M) polymorphism in individuals encoding for KIR2DL2.

To determine the functional consequences of these KIR2DL2-associated polymorphisms within HIV-1 Vpu/Env, we constructed HIV-1 viral variants, using an NL4-3 backbone^[@R11]--[@R12]^, that either encoded the Vpu71M/74H (Env17W/20M) sequence observed in KIR2DL2+ individuals (referred to as Vpu-Env^V/V^, with "V" standing for variant), or the Vpu71R/74L (Env17G/20L) sequence that was most commonly observed in KIR2DL2^neg^ subjects (referred to as Vpu-Env^WT/WT^). No significant differences were observed in the ability of the viral variants to replicate in primary CD4+ T cells *in vitro* ([Supplemental Figure 2A](#SD1){ref-type="supplementary-material"}). We subsequently assessed whether the different viral variants had any impact on NK cell recognition and/or antiviral activity. Primary CD4+ T cells were infected with viruses either containing the Vpu-Env^V/V^ or the Vpu-Env^WT/WT^ sequence, and then placed in coculture with autologous NK cells derived from KIR2DL2+ or KIR2DL2^neg^ HIV-1 negative individuals ([Figure 1](#F1){ref-type="fig"}). Both viruses replicated well in the presence of KIR2DL2^neg^ NK cells, with less than half a log inhibition of viral replication in the presence of NK cells compared to replication in CD4+ T cells alone ([Figure 1A and 1 B](#F1){ref-type="fig"}). In contrast, the Vpu-Env^WT/WT^ virus was significantly inhibited by NK cells derived from KIR2DL2+, but not KIR2DL2^neg^ subjects ([Figure 1B](#F1){ref-type="fig"}). Taken together, the Vpu-Env^V/V^ virus containing polymorphisms that were strongly associated with the presence of KIR2DL2 on the population level was not inhibited by KIR2DL2+ NK cells *in vitro*, while the "wild-type" variant (Vpu-Env^WT/WT^) rarely observed in KIR2DL2+ individuals was strongly inhibited by KIR2DL2+ NK cells, consistent with the selection of Vpu-Env^V/V^ viruses in KIR2DL2+ individuals.

To further elucidate the mechanism of KIR2DL2+ NK cell-mediated inhibition of replication of Vpu-Env^WT/WT^ viruses, we monitored the induction of CD107a expression on NK cells *in vitro* following stimulation with autologous CD4+ T cells infected with either the Vpu-Env^WT/WT^ or the Vpu-Env^V/V^ virus ([Figure 2A--C](#F2){ref-type="fig"}). In line with the viral inhibition data, CD158b+ NK cells from KIR2DL2+ individuals were strongly activated by CD4+ T cells infected with the Vpu-Env^WT/WT^ virus, but not by CD4+ T cells infected with the Vpu-Env^V/V^ virus ([Figure 2A--C](#F2){ref-type="fig"}). Taken together, these data are consistent with a model in which the inhibitory NK cell receptor KIR2DL2 does not bind to cells infected with HIV-1 strains containing the Vpu-Env^WT/WT^ sequence, but can bind to cells infected with HIV-1 Vpu-Env^V/V^, providing a strong inhibitory signal to KIR2DL2+ NK cells thereby protecting cells infected with Vpu-Env^V/V^ viruses from NK cell lysis.

KIR2DL2 segregates as an allele of the same locus with KIR2DL3^[@R13]^, and is in strong linkage disequilibrium with KIR2DS2 (Wn = 0.976, p \< 0.001). All but three individuals in our cohort that expressed KIR2DL2 also expressed KIR2DS2; however, these three individuals also encoded for the Vpu-Env^V/V^ polymorphism, suggesting that KIR2DL2, and not KIR2DS2 is responsible for the association with this polymorphism. To test whether KIR2DL2 was directly involved in the recognition of the viral variants, a KIR2DL2-Ig fusion construct was used to assess whether the Vpu-Env^V/V^ polymorphism modulated the interaction of KIR2DL2 with HIV-1-infected CD4+ T cells. The KIR2DL2 fusion construct bound robustly to all HIV-uninfected CD4+ T cells and also stained CD4+ T cells infected with the HIV-1 Vpu-Env^V/V^ variant significantly better than CD4+ T cells from the same donor infected with the Vpu-Env^WT/WT^ variant ([Figure 2D--F](#F2){ref-type="fig"}). In contrast, the binding of a KIR2DL3 fusion construct to HIV-1-infected CD4+ T cells was not affected by the KIR2DL2-associated polymorphism ([Figures 2E--F](#F2){ref-type="fig"}). HLA-C group 1 and group 2 molecules serve as the ligands for the inhibitory receptor KIR2DL2, which has been shown to bind with greater affinity for HLA-C group 1^[@R13]^. Staining with the KIR2DL2 fusion construct was consistent with these results, and highest using cells from individuals homozygous for HLA-C1 group ([Supplemental Figure 3](#SD1){ref-type="supplementary-material"}). In line with these binding data, the Vpu-Env^V/V^ polymorphisms were significantly enriched in KIR2DL2+ individuals homozygous for HLA-C group 1 (p = 0.008 for Vpu71M and p = 0.01 for Vpu74H). Taken together, these data suggest that the Vpu-Env^V/V^ polymorphism enhances the ability of the inhibitory receptor KIR2DL2 to bind to HIV-1-infected cells, in particular those expressing the higher affinity ligands for KIR2DL2.

In addition to the Vpu71M/74H polymorphism, two additional amino acid polymorphisms (Gag138L/I and Nef9S/K) were associated with the presence of the KIR2DL2 gene in the study population ([Table 1](#T1){ref-type="table"}, polymorphisms \# 2 and \#22). We next determined whether these KIR2DL2-associated polymorphisms were also associated with differential recognition of HIV-1-infected cells by KIR2DL2+ NK cells. Viruses containing the respective polymorphisms replicated similarly in CD4+ T cells ([Supplemental Figure 2B](#SD1){ref-type="supplementary-material"}). As observed for the Vpu/Env variants, viruses containing the amino acids that were rarely observed in KIR2DL2+ individuals (Gag^WT^ and Nef^WT^, [Table 2](#T2){ref-type="table"} and [Supplemental Tables 4 and 5](#SD2){ref-type="supplementary-material"}) were inhibited significantly stronger by NK cells derived from KIR2DL2+ individuals than were viruses containing the variants selected in KIR2DL2+ subjects ([Figure 3A and C](#F3){ref-type="fig"}). KIR2DL2+ NK cells furthermore degranulated more robustly in response to CD4+ T cells infected with the Gag^WT^ and Nef^WT^ viruses ([Figure 3B and 3D](#F3){ref-type="fig"}), and KIR2DL2-IgG fusion constructs bound significantly less to CD4+ T cells infected with the Gag^WT^ and Nef^WT^ viruses ([Figure 4A--C](#F4){ref-type="fig"}). Taken together, these data demonstrate that HIV-1 may evolve in KIR2DL2+ individuals to exclude particular amino acid polymorphisms in an effort to escape recognition by KIR2DL2+ NK cells.

Increasing evidence suggests that NK cells play an important role in the control of HIV-1 infection^[@R4]--[@R6]^. Here we report a number of amino acid polymorphisms within the HIV-1 clade B sequence that are significantly associated with the expression of specific KIR genes on the population level, and demonstrate in functional studies that these "KIR footprints" can modulate the interaction of KIR+ NK cells with HIV-1-infected CD4+ T cells. The selection of particular amino acid residues that result in enhanced binding of inhibitory KIRs to infected cells represents a novel approach by which HIV-1 can evade NK cell-mediated immunity. The molecular mechanisms and precise receptor/ligand interactions involved in this evasion from NK cell recognition require further investigation. Previous *in vitro* studies have demonstrated that sequence variations in HLA class I presented epitopes^[@R14]--[@R23]^ and small changes in the peptide repertoire presented on HLA class I molecules^[@R24]^ can both modulate the binding of KIR, providing a potential mechanism for virus sequence-dependent recognition of infected cells by NK cells. The KIR2DL2-associated sequence polymorphisms studied here had no impact on KIR2DL2-binding to HLA-Cw\*0102-expressing TAP-deficient T2 cells ([Supplemental Figure 4](#SD1){ref-type="supplementary-material"}), despite some degree of HLA-Cw\*0102 stabilization. However, several different HLA-C group 1 molecules might present epitopes within these regions of HIV-1, resulting in differential recognition by KIR2DL2. Additionally other mechanisms than the modulation of KIR-binding to HLA class I by viral sequence polymorphisms might account for the observed reduction in recognition of variant virus infected cells by KIR2DL2+ NK cells. KIR-associated sequence polymorphisms within HIV-1 proteins might directly modulate the ability of these proteins to be processed and presented^[@R25]^, subtly alter hydrostatic interactions with KIR, or change the profile of NK cell receptor ligands expressed on infected cells, as described for HIV-1 Nef, Vpu and Vpr ^[@R26]--[@R27]^.

Protective effects of specific KIRs or KIR/HLA class I combinations have been described for many infectious disease, including HIV, HCV, and HPV. While KIR2DL2 has not been identified as a protective KIR gene in any of these viral infections, homozygosity of its allotypic counterpart, KIR2DL3, has been associated with the resolution of HCV infection when co-expressed with its ligand, HLA-C group 1^[@R28]^. This protective KIR2DL3/HLA-C group 1 combination provides a weaker inhibitory signal, resulting in weaker inhibition of NK cells^[@R28]^. Here we describe a mechanism by which HIV-1 selects for sequence polymorphisms in KIR2DL2+ individuals that lead to an enhanced binding of this inhibitory KIR to infected cells, resulting in the inhibition of NK cell function, and thereby escaping the potential protective role of this KIR. Overall, the data from different viral infections are consistent with a model in which enhanced NK cell activity can contribute to the control of viral replication, and suggest that viruses can evade this NK cell-mediated immune pressure by selecting for variants that modulate the recognition of infected cells by KIR.

Methods summary {#S1}
===============

*Viral sequencing:* Genomic DNA was extracted from peripheral blood mononuclear cell samples and nested PCR protocols were used to amplify HIV-1 genomes^[@R9]^. *Phylogenetic analysis of KIR-associated sequence polymorphisms:* A decision-tree approach, followed by adjustment for multiple comparisons^[@R10]^, was used to identify KIR-associated sequence polymorphisms. *Construction of viruses containing sequence polymorphisms:* Mutations of interest were inserted into the HIV-1 NL4-3 backbone by GeneTailor site-directed mutagenesis system^[@R11]--[@R12]^. *Viral Inhibition Assay:* Viral inhibition assays were performed following infecting CD4+ T cells with the viral constructs, as indicated. The level of viral inhibition was then calculated as the difference in viral production (p24 Gag) in wells containing autologous NK cells compared to those containing CD4+ T cells alone^[@R6]^. *NK cell degranulation assay:* KIR2DL2+ NK cell degranulation was examined by flow-cytometry following NK cell co-culture with autologous CD4+ T cells infected the viral construct as indicated in the presence of Golgi-stop and anti-CD107a-PECy5 for 6 h^[@R29]^. NK cells were stained with anti-CD3, -CD56, -CD16, and -CD158b (KIR2DL2/2DL3/2DS2) antibodies, and the level of degranulation was assessed as the proportion of CD107a+ NK cells belonging to the CD158b+ NK cells.

Methods {#S2}
=======

Study subjects {#S3}
--------------

Ninety-one chronic untreated HIV-1 subtype B-infected subjects for which HLA class I and KIR genotypes were available ([Supplemental Table 1](#SD2){ref-type="supplementary-material"}) were included in this study^[@R9]^. In addition, 100 HIV-1 negative controls were genotyped for KIR/HLA genotypes. Of this large cohort of uninfected controls, a group 15 subjects that were KIR2DL2+ (KIR2DL2+/KIR2DL3+) and 15 subjects that were KIR2DL2- (KIR2DL3+/KIR2DL3+) were enrolled to provide samples for the generation of NK cells and autologous CD4+ target cells ([Supplemental Table 6](#SD2){ref-type="supplementary-material"}). For these *in vitro* studies, only individuals that did not encode for KIR3DS1 and HLA-B Bw4-80I were selected, as we had previously observed very strong inhibition of HIV-1 replication *in vitro* in individuals encoding this combined KIR/HLA genotype^[@R6]^. All study subjects were enrolled in Boston through the Massachusetts General Hospital, the Lemuel-Shattuck Hospital, and the Fenway Community Health Center. The study was approved by the Massachusetts General Hospital Review Board, and all subjects gave written informed consent.

Viral sequencing {#S4}
----------------

Genomic DNA was extracted from peripheral blood mononuclear cell samples and nested PCR protocols were used to amplify HIV-1 genomes as described previously^[@R9]^. Five independent PCR products of each sample were pooled and directly population sequenced at the Massachusetts General Hospital DNA Sequencing Core facility using clade B consensus sequencing primers as previously described^[@R9]^.

HLA class I and KIR typing {#S5}
--------------------------

High resolution HLA class I typing and KIR genotyping were performed as described previously^[@R6]^.

Phylogenetic analysis of KIR-associated sequence polymorphisms {#S6}
--------------------------------------------------------------

We used the decision-tree approach, which corrects for phylogenetic structure among the sequences and allows for a multivariate analysis^[@R10]^, to identify KIR-associated sequence polymorphisms. All results were adjusted for multiple comparisons (both p- and q-values are assigned to each result). For each protein analyzed, a maximum likelihood phylogenetic tree was constructed from the corresponding sequences. For every KIR/HLA gene, amino-acid position, and amino acid at that position, two generative, or directed graphical, models of the observed presence or absence of the amino acid in each sequence were created - one representing the null hypothesis that the observations are generated by the phylogenetic tree alone, and the other representing the alternative hypothesis that additional escape or reversion takes place due to KIR/HLA pressure in the subjects for which the sequences are observed. The likelihood of the observations was then maximized over the parameters of both models using an Expectation-Maximization algorithm, and a p value was computed using a likelihood ratio test based on those likelihoods^[@R10]^. To increase power, the tests were binarized, such the presence or absence of a given KIR/HLA gene was correlated with the presence or absence of a given amino acid. In addition, KIR-polymorphism pairs were analyzed only when the actual or expected count in every cell of the corresponding two-by-two contingency table was greater than or equal to three. For every amino-acid at each position, the KIR/HLA gene with the strongest association (and its corresponding p-value) was added to the list of identified associations. The analysis was then repeated after removing individuals having or possibly having this KIR/HLA gene. This procedure was iterated until no KIR/HLA gene yielded an association with p-value less than 0.05. A q-value statistic, estimating the proportion of false positives among the associations identified, was computed for each association by repeating this analysis on null data (generated by permuting the KIR/HLA data). Correction for multiple comparisons was undertaken both using q\<0.05 (estimating 5% false positives) and using q\<0.2 (estimating 20% false positives).

Construction of viruses containing sequence polymorphisms {#S7}
---------------------------------------------------------

HIV-1 strain NL4-3 was modified to express one or two mutations in *vpu/env, nef* or *gag* using the GeneTailor site-directed mutagenesis system (Invitrogen) or the QuikChange Lightning Site-Directed Mutagenesis system (Stratagene)^[@R11]--[@R12]^. In brief, mutagenesis was performed using 5' oligonucleotide primers Vpu_M71R-f (CTTGTGGAGATGGGGGTGGAAA[G]{.ul}GGGGCACCAT \[nt\] 6279), Vpu_M71R-r (TTTCCACCCCCATCTCCACAAGTGCTGATACTTCT \[nt\] 6234), Vpu_H74L-f (ATGGGGGTGGAAATGGGGCACC[T]{.ul}TGCTCCTTGG \[nt\] 6288), Vpu_H74L-r (GGTGCCCCATTTCCACCCCCATCTCCACAAG \[nt\] 6247), Vpu\_ M71R/H74L-f (ATGGGGGTGGAAA[G]{.ul}GGGGCACC[T]{.ul}TGCTCCTTGG \[nt\] 6288), and Vpu\_ M71R/H74L-r (GGTGCCCC[C]{.ul}TTTCCACCCCCATCTCCACAAG \[nt\] 6247); Nef/S9K-f (GTGGTCAAA[AA]{.ul}GTAAAGTGATTGGATGGCC), Nef/S9K-r (GGCCATCCAATCAC[TT]{.ul}TACTTTTTGACCAC); Gag/L138I-f (CCTATAGTGCAGAAC[AT]{.ul}CCAGGGGCAAATGG), Gag/L138I-r (CCATTTGCCCCTGG[AT]{.ul}GTTCTGCACTATAGG). Mutated nucleotides are underlined, and primer positions are numbered according to those of NL-4-3 (GenBank accession number AF324493). The complete HIV-1 coding region of the variant proviruses was sequenced on an ABI3730 XL DNA analyzer. Propagation of provirus, and generation of viral stocks was performed as previously described^[@R11]--[@R12]^. While the full length sequence of the NL4-3 viruses differed from the autologous sequence of the respective study subjects, the areas flanking the Vpu, Gag and Nef sequences studied were identical between the NL4-3 virus and the respective areas of interest, and only differed in the respective amino acids indicated in the respective Tables and [Supplemental Table](#SD2){ref-type="supplementary-material"}.

Viral Inhibition Assay {#S8}
----------------------

Viral inhibition assays using NK cells were performed as previously described^[@R6]^. CD4+ T cells that were generated after 4 days in culture with a bispecific antibody to CD3/CD8 were infected with lab strains containing the amino acid polymorphisms as indicated at a multiplicity of infection of 0.01 for 4 h at 37°C. Cells were washed two times. Equal numbers of CD4+ T cells were plated at NK cell/CD4+ T cell ratios of 10:1, or alone for 14 days in the presence of 50 U/ml IL-2. Supernatant was collected every 3--4 days for quantification of p24 Gag production by ELISA (p24 ELISA; Perkin Elmer).

NK cell degranulation assay {#S9}
---------------------------

To examine whether KIR2DL2+ NK cells specifically degranulated in response to autologous CD4+ T cells infected with either of the viral variants, we monitored the level of CD107a up-regulation on KIR2DL2+ or KIR2DL2- NK cells^[@R29]^. HIV-1 negative donors were selected that expressed KIR2DL2 in the absence of KIR2DS2 (referred to as KIR2DL2+), or that expressed KIR2DL3 in the absence of KIR2DL2 and KIR2DS2 (referred to as KIR2DL2^neg^). An anti-CD158b antibody was used to detect KIR2DL2-, KIR2DL3-, and KIR2DS2-expressing NK cells. The level of degranulation was assessed as the proportion of CD107a+ NK cells belonging to the CD158b+ NK cells. Thus purified NK cells were co-cultured in the presence of autologous CD4+ T cells infected *in vitro* with the respective HIV-1 strains for 7 days. Monensin was added to co-cultures on day 7 at 0.3 µg/ml in the presence of 20 µl CD107a--PE-Cy5 for 6 h. Cells were washed and stained with CD3-Pacific Blue, CD56-PECy7, CD16-APCCy7 (BD Biosciences), and CD158b-PE (Beckman Coulter) for 30 min, washed, and fixed in 1% paraformaldehyde until flow cytometric analysis was performed (FACSCalibur; BD Biosciences).

KIR-IgG-fusion construct binding assay {#S10}
--------------------------------------

Differences in the ability of KIR2DL2 or KIR2DL3 to interact with CD4+ T cells infected with either of the viral variants were ascertained using a KIR2DL2- and KIR2DL3-fusion construct (kindly provided by Drs. Eric Long, Salim Khakoo and Ofer Mandelboim). Thus PBMCs were obtained from HLA-C1/C1 homozygotes, -C1/C2 heterozygotes, or -C2/C2 homozygotes and were treated with 0.3ug of a bispecific CD3/8-antibody in the presence of 50 units of IL-2/ml of complete medium. After 3 days, the cells were infected with one of the 3 KIR2DL2-variants (Vpu 71/74, Gag 138, or Nef 9) or wildtype for 2 days. The cells were then collected and stained with 2ul of the KIR2DL2- or KIR2DL3-Fc for 1 hour on ice. The cells were then washed and stained with a secondary APC-goat- anti-human antibody for an additional 20 minutes on ice. In parallel, of infected cells were stained with the secondary anti-human antibody alone to define the background level of staining. All tubes were then fixed with 100ul of Fix A (Invitrogen) solution for 10 minutes, washed and permeabilized using 100ul of Perm B (Invitrogen). The tubes were then stained for intracellular p24 using the KC-57-RD1 antibody for 20 minutes on ice, and then washed. The tubes were then fixed in 1% paraformaldehyde until flow cytometric analysis was performed (FACSCalibur; BD Biosciences).

HLA class I stabilization assays {#S11}
--------------------------------

HLA-C stabilization was assessed in 2×10'5 T2 cells that were incubated with 0.04mg/ml peptide, as indicated, overnight at 26°C. The following day peptide-pulsed T2 cells were stained with DT9 antibody (HLA-C/E) for 30mins at 4°C. Cells were then washed in PBS before staining with anti-mouse IgG-PE (Sigma) for 30mins at 4°C. Cells were washed twice with PBS and fixed in Perm A solution (BD). KIR2DL2-Fc binding to peptide-pulsed T2 cells was assessed as previously described (24).
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![KIR2DL2 associated sequence polymorphisms result in a loss of NK cell inhibition of HIV replication *in vitro*\
(A) The Vpu-Env^WT/WT^ virus was inhibited more robustly by NK cells derived from a KIR2DL2+ individual (gray lines) compared to the Vpu-Env^V/V^ virus. NK cells derived from a KIR2DL2^neg^ (black lines) individual did not inhibit either virus. (B) Similarly, the Vpu-Env^WT/WT^ virus was inhibited significantly more strongly by NK cells derived from individuals that expressed KIR2DL2 (dark grey bars, n=6) than the Vpu-Env^V/V^ virus (black bars). NK cells derived from individuals that did not express KIR2DL2 (white bars, n=6) did not significantly inhibit either virus. \* p \< 0.05; \*\* p \< 0.005; + KIR2DL2^pos^; - KIR2DL2^neg^.](nihms313004f1){#F1}

![Amino acid polymorphisms at positions 71/74 in VPU inhibit KIR2DL2, but not KIR2DL3, recognition and binding\
The flow cytometric plots depict the frequency of total CD158b (KIR2DL2/2DL3/2DS2)+ NK cells that degranulated following coculture with autologous CD4+ T cells infected with the Vpu-Env^WT/WT^ virus or the Vpu-Env^V/V^ virus for 2 representative subjects (left 2DL2+ subjects; right 2DL2- subject; dot plots (A)). Furthermore, the frequency of degranulating CD158+ NK cells of the total CD158+ NK cell population is also represented for both the KIR2DL2+ (top) and KIR2DL2- (bottom) donor in histograms for both the WT/WT (black line) and the V/V virus (grey line) (B). Figure 2 C shows the combined data for NK cell degranulation in 2DL2+ (n=5) and 2DL2- (n=5) individuals. \*p \< 0.05. The dot plots in figure 2D depict the staining pattern of a KIR2DL2-fusion construct on HIV-infected CD4+ T cells from an HLA-C1/C2 heterozygous donor, and the histogram in figure 2E demonstrates the staining of KIR2DL2- and KIR2DL3-IgG fusion constructs on the same donors for the 2 viral variants. In figure 2F KIR2DL2-IgG- (black) and KIR2DL3-IgG-fusion construct (grey) binding data are summarized for a total of 5 different HLA-C1 heterozygous CD4+ T cell donors for the 2 viral variants in the bar graph. \*\* p \< 0.005.](nihms313004f2){#F2}

![Two additional KIR2DL2-associated amino acid polymorphisms reduce KIR2DL2-mediated NK cell recognition of virally infected cells\
NK cells from KIR2DL2+ individuals (gray bars, n=5) inhibited the replication of the Gag-WT virus and the Nef-WT virus significantly better than the replication of the Gag-V and Nef-V virus (A and C). Similarly, NK cells derived from KIR2DL2+ individuals (gray bars, n=5) were activated significantly more by cells infected with the Gag-WT However, NK cells derived from KIR2DL2- individuals did not inhibit viral replication or degranulate in the response to cells infected with either of the WT or V viruses. \* p \< 0.05.](nihms313004f3){#F3}

![KIR2DL2-associated amino acid polymorphisms affect KIR2DL2-, but not KIR2DL3-binding to infected CD4+ T cells\
CD4+ T cells infected with the respective variant viruses were stained with KIR2DL2-IgG and KIR2DL3-IgG fusion constructs. The dot plots (A) and histograms (B) depict the staining pattern of KIR2DL2-IgG and KIR2DL3-IgG fusion constructs of HIV-1-infected CD4+ T cells from a HLA-C1/C2 heterozygous donor. The bar graph summarizes KIR2DL2- (black) or KIR2DL3- (grey) IgG fusion construct binding data for 5 different HLA-C1/C2 heterozygous CD4+ T cell donors for the viral variants, as indicated (C). \*\* p \< 0.005](nihms313004f4){#F4}

###### 

KIR footprints in HIV-1 sequence

       Protein   aa position   KIR-association   Consensus aa[\*](#TFN1){ref-type="table-fn"}   q-value
  ---- --------- ------------- ----------------- ---------------------------------------------- ---------
  1    Gag       93            KIR2DS3           E                                              0.1389
  2    Gag       138           KIR2DL2           L                                              0.1852
  3    Gag       138           KIR2DS2           L                                              0.1852
  4    Gag       371           KIR2DS5           T                                              0
  5    Gag       389           KIR3DS1           T                                              0
  6    Gag       479           KIR2DS1           I                                              0
  7    Vpr       37            KIR2DS3           I                                              0.0909
  8    Tat       3             KIR2DL2           S                                              0.0246
  9    Tat       3             KIR2DS2           S                                              0
  10   Tat       3             KIR3DS1           S                                              0.1311
  11   Tat       9             KIR2DS3           P                                              0.1311
  12   Tat       28            KIR2DS1           V                                              0.1311
  13   Tat       28            KIR2DS5           V                                              0.1339
  14   Vpu       3             KIR2DL3           S                                              0.0833
  15   Vpu       71            KIR2DL2           M                                              0.125
  16   Vpu       74            KIR2DL2           H                                              0.1354
  17   Env       17            KIR2DL2           W                                              0
  18   Env       20            KIR2DL2           M                                              0.1667
  19   Env       46            KIR3DS1           K                                              0.1667
  20   Env       347           KIR2DS1           L                                              0.2
  21   Env       595           KIR2DS1           I                                              0.2
  22   Nef       9             KIR2DL2           S                                              0.0833

HIV-1 consensus sequence in 91 study subjects

###### 

Frequency of amino acid polymorphisms among KIR2DL2+ and KIR2DL2- subjects

  -------------- --------- ------- ------- -------------- ------- ------- --------- ------- ------- -------- ----------------- -----------------
  **VPU**\       **E**\    **M**   **G**   **H**          **H**   **A**   **P**     **W**   **D**   **V**\   **Percent of**\   **Number of**\
  aa position    70                                                                                 79       **indivdiuals**   **Individuals**

                                                                                                                               

  **KIR2DL2+**   .         .       .       .              .       .       .         .       .       .        72                (34/47)

  .              L/Q/-     .       .       D              .       .       .         .       .       24       (11/47)           

  .              R         .       .       L              .       .       .         .       .       4        (2/47)            

                                                                                                                               

  **KIR2DL2-**   ./D       .       ./E     ./Q            .       ./D     .         .       .       .        32                (14/44)

  ./H/M          N/V/Q/G   ./A     .       D/R            .       ./L     ./G       ./V     ./I     34       (15/44)           

  ./H            R         .       ./R     L              .       ./L     ./G/R/L   ./V     ./I     34       (15/44)           

                                                                                                                               

  **ENV**\       **R**\    **W**   **G**   **T**          **M**   **L**   **L**     **G**   **M**   **L**\   **Percent of**\   **Number of**\
  aa position    16                                                                                 25       **indivdiuals**   **Individuals**

                                                                                                                               

  **KIR2DL2+**   .         .       .       .              .       .       .         .       .       .        85                (40/47)

  ./K            R/.       .       I       T/.            .       .       .         .       .       11       (5/47)            

  ./K            G         .       I/A     L              ./F     .       .         ./L/I   .       4        (2/47)            

                                                                                                                               

  **KIR2DL2-**   .         .       .       ./I            .       .       .         .       .       .        43                (19/44)

  .              R/M       .       ./I     ./V            .       .       .         .       .       23       (10/44)           

  ./K            G         .       ./I     L              .       .       .         .       .       34       (15/44)           

                                                                                                                               

  **GAG**\       **I**\    **V**   **Q**   **N**          **L**   **Q**   **G**     **Q**   **M**   **V**\   **Percent of**\   **Number of**\
  aa position    134                                                                                143      **indivdiuals**   **Individuals**

                                                                                                                               

  **KIR2DL2+**   .         .       .       .              .       .       .         .       .       ./I      68                (32/47)

  ./V            .         .       .       M/V/A          .       .       .         .       ./I     32       (15/47)           

  .              .         .       .       I              .       .       .         .       .       0        (0/47)            

                                                                                                                               

  **KIR2DL2-**   .         .       ./R     .              .       .       .         .       .       .        57                (25/44)

  .              .         ./R     .       ./M/V/A        .       .       .         .       .       25       (11/44)           

  .              .         .       .       I              .       .       .         .       .       18       (8/44)            

                                                                                                                               

  **NEF**\       **W**\    **S**   **K**   **R**          **S**   **V**   **V**     **G**   **W**   **P**\   **Percent of**\   **Number of**\
  aa position    5                                                                                  14       **indivdiuals**   **Individuals**

                                                                                                                               

  **KIR2DL2+**   ./X       .       .       ./X            .       ./X     ./X       ./X     .       ./X      75                (35/47)

  ./X            .         .       ./X     E/R/N/C/L/-    ./X     ./X     ./E       .       ./X     23       (11/47)           

  .              .         .       .       K              E       N       .         .       S       2        (1/47)            

                                                                                                                               

  **KIR2DL2-**   ./C       .       ./R     ./X            .       ./X     ./X       ./X     .       ./X      52                (23/44)

  ./C            .         ./R     ./X     ./P/R/I/G/W/   ./X     ./X     ./X       .       ./X     27       (12/44)           

  .              .         .       ./X     K              ./X     ./X     ./D       .       ./S     21       (9/44)            
  -------------- --------- ------- ------- -------------- ------- ------- --------- ------- ------- -------- ----------------- -----------------

[^1]: These authors contributed equally to the work in this manuscript
